IONIS PHARMACEUTICALS (IONS) stock: insider trades, news & valuation
Net selling
Close · Oct 9, 2026
$45.28
+4.6% on the day
-35.6% over 12 months
52-week range $43.30 – $86.50
Share price and insider trades
IONS closeInsider buyInsider sale
Bought, 12 months$1.1M
Sold, 12 months$137M
Insiders buying1
Insiders selling19
IONIS PHARMACEUTICALS insider trading at a glance (Oct 9, 2026): in the past 12 months, 1 insider bought $1.1M and 19 sold $137M of IONS stock on the open market.
Get emailed when insiders cluster-buy stocks like IONS
Free alerts the day a new cluster buy is filed, plus the Monday report of the week's biggest insider trades.
Free · unsubscribe anytime · not investment advice · see a sample issue
IONS insider buying and selling by quarter
Open-market purchases (green, above the line) and sales (red, below), by trade date.
| Quarter | Bought | Purchases | Sold | Sales |
|---|---|---|---|---|
| Q4 2026 | — | 0 | — | 0 |
| Q3 2026 | $1.1M | 2 | $3.5M | 6 |
| Q2 2026 | — | 0 | $26.5M | 26 |
| Q1 2026 | — | 0 | $82.8M | 67 |
| Q4 2025 | — | 0 | $33.7M | 42 |
| Q3 2025 | — | 0 | $8.7M | 4 |
Valuation, profit and volume
P/E (trailing)n/aSector median —
Market value—
Profit margin—Revenue growth —
Volume vs. 50-day1.0×Last 5 sessions
Insiders' paper profit−$153KOn all tracked purchases -14.5%
Summary
Over the past 12 months, 1 IONIS PHARMACEUTICALS INC insider reported open-market purchases totaling $1.1M, while 19 insiders reported sales totaling $137M. 118 of 145 recorded sales were made under pre-scheduled Rule 10b5-1 trading plans, which are usually less informative than discretionary sales.
Insider transactions
Open-market purchases and sales.
| Filed | Insider | Type | Shares | Price | Value | Since | Score |
|---|---|---|---|---|---|---|---|
| Jul 31SEC | Michael R HaydenDirector | Buy | 15,00019,000 held (+375%) | $53.38 | $801K | -15.2% | — |
| Jul 31SEC | Michael R HaydenDirector | Buy | 5,00024,000 held (+26%) | $51.60 | $258K | -12.2% | — |
| Jul 9SEC | C Frank BennettEvp, Chief Scientific Officer | Sell Plan | 15,000 | $85.46 | $1.3M | -47.0% | — |
| Jul 9SEC | Allene M. DiazDirector | Sell Plan | 10,1113,811 held (−73%) | $85.42 | $864K | -47.0% | — |
| Jul 9SEC | C Frank BennettEvp, Chief Scientific Officer | Sell Plan | 5,53675,018 held (−7%) | $83.58 | $463K | -45.8% | — |
| Jul 9SEC | Holly B. KordasiewiczEvp, Chief Development Officer | Sell Plan | 36222,096 held (−2%) | $84.30 | $31K | -46.3% | — |
| Jul 6SEC | Joseph Klein IIIDirector | Sell Plan | 11,41911,014 held (−51%) | $79.04 | $903K | -42.7% | — |
| Jul 6SEC | Joseph Klein IIIDirector | Sell Plan | 9922,433 held (−0%) | $79.45 | $8K | -43.0% | — |
| Jun 30SEC | Eugene SchneiderEvp, Chf Clinical Develop Ofcr | Sell Plan | 26,00077,114 held (−25%) | $81.05 | $2.1M | -44.1% | — |
| Jun 30SEC | Joseph BaroldiEvp, Chief Business Officer | Sell Plan | 5,6354,669 held (−55%) | $80.16 | $452K | -43.5% | — |
| Jun 30SEC | Patrick R. O'neilGeneral Counsel | Sell Plan | 3,06961,470 held (−5%) | $80.00 | $246K | -43.4% | — |
| Jun 26SEC | Brett P MoniaCEO | Sell Plan | 50,000245,571 held (−17%) | $80.59 | $4.0M | -43.8% | — |
| Jun 26SEC | Brett P MoniaCEO | Sell Plan | 21,072245,571 held (−8%) | $78.49 | $1.7M | -42.3% | — |
| Jun 26SEC | Brett P MoniaCEO | Sell Plan | 14,565245,571 held (−6%) | $78.41 | $1.1M | -42.3% | — |
| Jun 26SEC | Eric SwayzeEvp Research | Sell Plan | 10,60221,759 held (−33%) | $79.18 | $839K | -42.8% | — |
| Jun 16SEC | Holly B. KordasiewiczEvp, Chief Development Officer | Sell Plan | 41,00442,300 held (−49%) | $73.09 | $3.0M | -38.0% | — |
| Jun 16SEC | Holly B. KordasiewiczEvp, Chief Development Officer | Sell Plan | 19,84222,458 held (−47%) | $74.05 | $1.5M | -38.9% | — |
| Jun 16SEC | Spencer R BerthelsenDirector | Sell Plan | 8,000156,013 held (−5%) | $73.49 | $588K | -38.4% | — |
| Jun 3SEC | Spencer R BerthelsenDirector | Sell Plan | 8,000156,013 held (−5%) | $75.67 | $605K | -40.2% | — |
| May 15SEC | Brett P MoniaCEO | Sell Plan | 3,220242,662 held (−1%) | $78.68 | $253K | -42.5% | — |
| May 15SEC | Brett P MoniaCEO | Sell Plan | 1,316242,662 held (−1%) | $78.01 | $103K | -42.0% | — |
| May 6SEC | Joseph LoscalzoDirector | Sell Plan | 59,50854,111 held (−52%) | $74.90 | $4.5M | -39.5% | — |
| May 6SEC | Joseph LoscalzoDirector | Sell Plan | 17,78136,330 held (−33%) | $75.58 | $1.3M | -40.1% | — |
| May 5SEC | Joseph Klein IIIDirector | Sell Plan | 8,68012,445 held (−41%) | $73.35 | $637K | -38.3% | — |
| May 5SEC | Joseph Klein IIIDirector | Sell Plan | 1,43111,014 held (−11%) | $74.45 | $107K | -39.2% | — |
| Apr 30SEC | Joseph BaroldiEvp, Chief Business Officer | Sell Plan | 1,62644,909 held (−3%) | $71.79 | $117K | -36.9% | — |
| Apr 17SEC | Joseph BaroldiEvp, Chief Business Officer | Sell | 5,61946,535 held (−11%) | $74.56 | $419K | -39.3% | — |
| Apr 17SEC | Kyle JenneEvp, Chf Gl Pdt Str Ofcr | Sell | 4,90223,713 held (−17%) | $75.17 | $368K | -39.8% | — |
| Apr 17SEC | B Lynne ParshallDirector | Sell Plan | 4,46651,878 held (−8%) | $76.19 | $340K | -40.6% | — |
| Apr 17SEC | Brian BirchlerEvp, Corp And Development Ops | Sell | 97367,500 held (−1%) | $75.04 | $73K | -39.7% | — |
| Apr 17SEC | B Lynne ParshallDirector | Sell Plan | 53451,344 held (−1%) | $76.97 | $41K | -41.2% | — |
| Apr 2SEC | Joseph Klein IIIDirector | Sell Plan | 20,10513,230 held (−60%) | $75.50 | $1.5M | -40.0% | — |
| Apr 2SEC | Shannon L. DeversEvp, Chief Human Resources Ofc | Sell Plan | 6,19316,348 held (−27%) | $74.05 | $459K | -38.9% | — |
| Apr 2SEC | Joseph Klein IIIDirector | Sell Plan | 2,21611,014 held (−17%) | $75.95 | $168K | -40.4% | — |
| Mar 23SEC | Eugene SchneiderEvp, Chf Clinical Develop Ofcr | Sell Plan | 5,81263,890 held (−8%) | $70.97 | $412K | -36.2% | — |
| Mar 18SEC | Elizabeth L HougenCFO | Sell Plan | 205,608102,272 held (−67%) | $72.38 | $14.9M | -37.4% | — |
| Mar 18SEC | Elizabeth L HougenCFO | Sell Plan | 10,17282,660 held (−11%) | $73.21 | $745K | -38.2% | — |
| Mar 18SEC | Elizabeth L HougenCFO | Sell Plan | 9,44092,832 held (−9%) | $72.77 | $687K | -37.8% | — |
| Mar 11SEC | Brett P MoniaCEO | Sell Plan | 117,604244,346 held (−32%) | $75.26 | $8.9M | -39.8% | — |
| Mar 11SEC | Kyle JenneEvp, Chf Gl Pdt Str Ofcr | Sell Plan | 21,19127,800 held (−43%) | $75.50 | $1.6M | -40.0% | — |
| Mar 11SEC | Brett P MoniaCEO | Sell Plan | 17,591242,662 held (−7%) | $76.34 | $1.3M | -40.7% | — |
| Mar 11SEC | Brett P MoniaCEO | Sell Plan | 16,512260,253 held (−6%) | $75.47 | $1.2M | -40.0% | — |
| Mar 11SEC | Kyle JenneEvp, Chf Gl Pdt Str Ofcr | Sell Plan | 16,08611,714 held (−58%) | $76.30 | $1.2M | -40.7% | — |
| Mar 11SEC | Patrick R. O'neilGeneral Counsel | Sell Plan | 10,14862,211 held (−14%) | $75.25 | $764K | -39.8% | — |
| Mar 11SEC | Brett P MoniaCEO | Sell Plan | 7,382361,950 held (−2%) | $74.11 | $547K | -38.9% | — |
| Mar 11SEC | Brett P MoniaCEO | Sell Plan | 1,684242,662 held (−1%) | $75.58 | $127K | -40.1% | — |
| Mar 5SEC | C Frank BennettEvp, Chief Scientific Officer | Sell Plan | 71,60094,043 held (−43%) | $79.10 | $5.7M | -42.8% | — |
| Mar 5SEC | Allene M. DiazDirector | Sell Plan | 39,26519,424 held (−67%) | $79.11 | $3.1M | -42.8% | — |
| Mar 5SEC | Allene M. DiazDirector | Sell Plan | 14,6084,816 held (−75%) | $79.88 | $1.2M | -43.3% | — |
| Mar 5SEC | Shannon L. DeversEvp, Chief Human Resources Ofc | Sell Plan | 14,32128,326 held (−34%) | $79.12 | $1.1M | -42.8% | — |
| Mar 5SEC | Joseph Klein IIIDirector | Sell Plan | 13,52618,820 held (−42%) | $79.17 | $1.1M | -42.8% | — |
| Mar 5SEC | C Frank BennettEvp, Chief Scientific Officer | Sell Plan | 12,68781,356 held (−13%) | $79.88 | $1.0M | -43.3% | — |
| Mar 5SEC | Joseph Klein IIIDirector | Sell Plan | 6,79412,026 held (−36%) | $80.00 | $544K | -43.4% | — |
| Mar 5SEC | Shannon L. DeversEvp, Chief Human Resources Ofc | Sell Plan | 5,03023,296 held (−18%) | $80.00 | $402K | -43.4% | — |
| Mar 5SEC | Joseph BaroldiEvp, Chief Business Officer | Sell Plan | 4,09641,317 held (−9%) | $79.36 | $325K | -42.9% | — |
| Mar 5SEC | Joseph BaroldiEvp, Chief Business Officer | Sell Plan | 2,0884,383 held (−32%) | $80.41 | $168K | -43.7% | — |
| Mar 5SEC | Joseph Klein IIIDirector | Sell Plan | 1,01211,014 held (−8%) | $80.82 | $82K | -44.0% | — |
| Mar 5SEC | Allene M. DiazDirector | Sell Plan | 1,0053,811 held (−21%) | $80.80 | $81K | -44.0% | — |
| Mar 5SEC | Joseph LoscalzoDirector | Sell Plan | 83236,330 held (−2%) | $80.33 | $67K | -43.6% | — |
| Mar 5SEC | C Frank BennettEvp, Chief Scientific Officer | Sell Plan | 80280,554 held (−1%) | $80.76 | $65K | -43.9% | — |
| Mar 5SEC | Shannon L. DeversEvp, Chief Human Resources Ofc | Sell Plan | 75522,541 held (−3%) | $80.84 | $61K | -44.0% | — |
| Mar 5SEC | Joseph BaroldiEvp, Chief Business Officer | Sell Plan | 2384,347 held (−5%) | $80.00 | $19K | -43.4% | — |
| Mar 5SEC | Joseph BaroldiEvp, Chief Business Officer | Sell Plan | 2014,347 held (−4%) | $80.00 | $16K | -43.4% | — |
| Mar 5SEC | Joseph LoscalzoDirector | Sell Plan | 20036,330 held (−1%) | $80.00 | $16K | -43.4% | — |
| Mar 5SEC | Joseph BaroldiEvp, Chief Business Officer | Sell Plan | 364,347 held (−1%) | $81.01 | $3K | -44.1% | — |
| Feb 13SEC | Eric SwayzeEvp Research | Sell Plan | 9,43538,312 held (−20%) | $81.56 | $770K | -44.5% | — |
| Feb 13SEC | Eric SwayzeEvp Research | Sell Plan | 6,20732,105 held (−16%) | $82.07 | $509K | -44.8% | — |
| Feb 13SEC | B Lynne ParshallDirector | Sell Plan | 5,00056,344 held (−8%) | $82.72 | $414K | -45.3% | — |
| Feb 10SEC | Brett P MoniaCEO | Sell Plan | 29,430254,497 held (−10%) | $85.79 | $2.5M | -47.2% | — |
| Feb 4SEC | C Frank BennettEvp, Chief Scientific Officer | Sell Plan | 48,62680,293 held (−38%) | $83.03 | $4.0M | -45.5% | — |
| Feb 4SEC | C Frank BennettEvp, Chief Scientific Officer | Sell Plan | 20,00080,293 held (−20%) | $82.60 | $1.7M | -45.2% | — |
| Feb 4SEC | C Frank BennettEvp, Chief Scientific Officer | Sell Plan | 16,46380,293 held (−17%) | $83.03 | $1.4M | -45.5% | — |
| Feb 2SEC | Brett P MoniaCEO | Sell | 62,970283,927 held (−18%) | $82.72 | $5.2M | -45.3% | — |
| Feb 2SEC | Elizabeth L HougenCFO | Sell | 6,988132,881 held (−5%) | $83.24 | $582K | -45.6% | — |
| Feb 2SEC | Patrick R. O'neilGeneral Counsel | Sell | 6,17971,983 held (−8%) | $83.53 | $516K | -45.8% | — |
| Feb 2SEC | Eugene SchneiderEvp, Chf Clinical Develop Ofcr | Sell | 6,17969,702 held (−8%) | $83.45 | $516K | -45.7% | — |
| Feb 2SEC | Brian BirchlerEvp, Corp And Development Ops | Sell | 6,17966,247 held (−9%) | $83.03 | $513K | -45.5% | — |
| Feb 2SEC | Eric SwayzeEvp Research | Sell | 6,17947,747 held (−11%) | $82.93 | $512K | -45.4% | — |
| Feb 2SEC | C Frank BennettEvp, Chief Scientific Officer | Sell | 5,885100,293 held (−6%) | $82.95 | $488K | -45.4% | — |
| Feb 2SEC | Joseph BaroldiEvp, Chief Business Officer | Sell | 5,29645,413 held (−10%) | $82.96 | $439K | -45.4% | — |
| Jan 23SEC | Shannon L. DeversEvp, Chief Human Resources Ofc | Sell Plan | 3,97722,541 held (−15%) | $81.34 | $323K | -44.3% | — |
| Jan 20SEC | Brett P MoniaCEO | Sell | 44,034224,683 held (−16%) | $74.82 | $3.3M | -39.5% | — |
| Jan 20SEC | Elizabeth L HougenCFO | Sell | 12,922126,307 held (−9%) | $75.22 | $972K | -39.8% | — |
| Jan 20SEC | Eric SwayzeEvp Research | Sell | 9,88441,935 held (−19%) | $75.34 | $745K | -39.9% | — |
| Jan 20SEC | Eugene SchneiderEvp, Chf Clinical Develop Ofcr | Sell | 9,30263,890 held (−13%) | $75.59 | $703K | -40.1% | — |
| Jan 20SEC | Patrick R. O'neilGeneral Counsel | Sell | 9,19166,171 held (−12%) | $75.84 | $697K | -40.3% | — |
| Jan 20SEC | C Frank BennettEvp, Chief Scientific Officer | Sell | 8,97794,757 held (−9%) | $75.15 | $675K | -39.7% | — |
| Jan 20SEC | Brian BirchlerEvp, Corp And Development Ops | Sell | 8,48060,435 held (−12%) | $75.11 | $637K | -39.7% | — |
| Jan 20SEC | Shannon L. DeversEvp, Chief Human Resources Ofc | Sell | 8,35326,518 held (−24%) | $75.95 | $634K | -40.4% | — |
| Jan 20SEC | Joseph BaroldiEvp, Chief Business Officer | Sell | 6,90740,431 held (−15%) | $75.75 | $523K | -40.2% | — |
| Jan 20SEC | Holly B. KordasiewiczEvp, Chief Development Officer | Sell | 4,14114,718 held (−22%) | $75.66 | $313K | -40.2% | — |
| Jan 20SEC | Kyle JenneEvp, Chf Gl Pdt Str Ofcr | Sell | 1,82316,389 held (−10%) | $75.96 | $138K | -40.4% | — |
| Jan 20SEC | Joseph BaroldiEvp, Chief Business Officer | Sell | 1,1494,772 held (−19%) | $75.78 | $87K | -40.2% | — |
| Jan 20SEC | Eric SwayzeEvp Research | Sell | 49318 held (−13%) | $75.97 | $4K | -40.4% | — |
| Jan 9SEC | Shannon L. DeversEvp, Chief Human Resources Ofc | Sell Plan | 25,54517,494 held (−59%) | $85.36 | $2.2M | -47.0% | — |
| Jan 9SEC | Shannon L. DeversEvp, Chief Human Resources Ofc | Sell Plan | 9,26417,494 held (−35%) | $84.62 | $784K | -46.5% | — |
| Jan 9SEC | Shannon L. DeversEvp, Chief Human Resources Ofc | Sell Plan | 3,82917,494 held (−18%) | $84.62 | $324K | -46.5% | — |
| Jan 9SEC | Shannon L. DeversEvp, Chief Human Resources Ofc | Sell Plan | 3,46017,494 held (−17%) | $84.62 | $293K | -46.5% | — |
| Jan 9SEC | Shannon L. DeversEvp, Chief Human Resources Ofc | Sell Plan | 2,10117,494 held (−11%) | $85.36 | $179K | -47.0% | — |
| Jan 6SEC | Eric SwayzeEvp Research | Sell Plan | 18,33830,453 held (−38%) | $79.27 | $1.5M | -42.9% | — |
| Jan 6SEC | Eric SwayzeEvp Research | Sell Plan | 5,12530,453 held (−14%) | $78.57 | $403K | -42.4% | — |
| Dec 3SEC | Joseph H WenderDirector | Sell Plan | 20,57143,464 held (−32%) | $80.67 | $1.7M | -43.9% | — |
| Dec 3SEC | Joseph H WenderDirector | Sell Plan | 7,42936,035 held (−17%) | $81.23 | $603K | -44.3% | — |
| Nov 28SEC | Shannon L. DeversEvp, Chief Human Resources Ofc | Sell Plan | 16,77717,494 held (−49%) | $80.91 | $1.4M | -44.0% | — |
| Nov 28SEC | Joseph Klein IIIDirector | Sell Plan | 4,000 | $80.00 | $320K | -43.4% | — |
| Nov 28SEC | Joseph Klein IIIDirector | Sell Plan | 4,000 | $80.00 | $320K | -43.4% | — |
| Nov 28SEC | Joseph Klein IIIDirector | Sell Plan | 4,000 | $80.00 | $320K | -43.4% | — |
| Nov 20SEC | Joan E HermanDirector | Sell | 32,00046,086 held (−41%) | $72.13 | $2.3M | -37.2% | — |
| Nov 20SEC | Joan E HermanDirector | Sell | 12,00046,086 held (−21%) | $72.13 | $866K | -37.2% | — |
| Nov 7SEC | Richard S GearyEvp, Chief Development Officer | Sell Plan | 18,30059,657 held (−23%) | $75.42 | $1.4M | -40.0% | — |
| Nov 7SEC | Richard S GearyEvp, Chief Development Officer | Sell Plan | 14,73859,657 held (−20%) | $76.10 | $1.1M | -40.5% | — |
| Nov 7SEC | Brian BirchlerEvp, Corp And Development Ops | Sell Plan | 8,00048,826 held (−14%) | $76.17 | $609K | -40.6% | — |
| Nov 7SEC | Richard S GearyEvp, Chief Development Officer | Sell Plan | 90559,657 held (−1%) | $75.05 | $68K | -39.7% | — |
| Nov 7SEC | Richard S GearyEvp, Chief Development Officer | Sell Plan | 80159,657 held (−1%) | $75.01 | $60K | -39.6% | — |
| Nov 7SEC | Richard S GearyEvp, Chief Development Officer | Sell Plan | 80059,657 held (−1%) | $75.01 | $60K | -39.6% | — |
| Nov 7SEC | Richard S GearyEvp, Chief Development Officer | Sell Plan | 77559,657 held (−1%) | $75.05 | $58K | -39.7% | — |
| Nov 3SEC | Richard S GearyEvp, Chief Development Officer | Sell Plan | 34,66479,657 held (−30%) | $75.11 | $2.6M | -39.7% | — |
| Nov 3SEC | Richard S GearyEvp, Chief Development Officer | Sell Plan | 34,58579,657 held (−30%) | $75.11 | $2.6M | -39.7% | — |
| Nov 3SEC | Richard S GearyEvp, Chief Development Officer | Sell Plan | 20,00059,657 held (−25%) | $75.11 | $1.5M | -39.7% | — |
| Nov 3SEC | Joseph LoscalzoDirector | Sell Plan | 16,00036,330 held (−31%) | $75.10 | $1.2M | -39.7% | — |
| Nov 3SEC | Joseph H WenderDirector | Sell Plan | 11,20064,035 held (−15%) | $75.16 | $842K | -39.8% | — |
| Nov 3SEC | Joseph H WenderDirector | Sell Plan | 8,34181,210 held (−9%) | $73.16 | $610K | -38.1% | — |
| Nov 3SEC | Joseph H WenderDirector | Sell Plan | 5,97575,235 held (−7%) | $73.85 | $441K | -38.7% | — |
| Nov 3SEC | Joseph H WenderDirector | Sell Plan | 2,48489,551 held (−3%) | $72.19 | $179K | -37.3% | — |
| Nov 3SEC | Richard S GearyEvp, Chief Development Officer | Sell Plan | 90559,657 held (−1%) | $75.05 | $68K | -39.7% | — |
| Nov 3SEC | Richard S GearyEvp, Chief Development Officer | Sell Plan | 77559,657 held (−1%) | $75.05 | $58K | -39.7% | — |
| Oct 16SEC | Brian BirchlerEvp, Corp And Development Ops | Sell Plan | 12,42556,826 held (−18%) | $72.23 | $897K | -37.3% | — |
| Oct 16SEC | Brian BirchlerEvp, Corp And Development Ops | Sell Plan | 11,47556,826 held (−17%) | $72.03 | $827K | -37.1% | — |
| Oct 16SEC | Shannon L. DeversEvp, Chief Human Resources Ofc | Sell Plan | 6,00015,937 held (−27%) | $72.94 | $438K | -37.9% | — |
| Oct 16SEC | B Lynne ParshallDirector | Sell Plan | 5,00061,344 held (−8%) | $71.74 | $359K | -36.9% | — |
| Oct 16SEC | Shannon L. DeversEvp, Chief Human Resources Ofc | Sell Plan | 1,26317,494 held (−7%) | $73.62 | $93K | -38.5% | — |
| Oct 16SEC | Eric SwayzeEvp Research | Sell | 53256 held (−17%) | $73.62 | $4K | -38.5% | — |
| Oct 8SEC | Patrick R. O'neilGeneral Counsel | Sell Plan | 10,20057,130 held (−15%) | $69.89 | $713K | -35.2% | — |
| Oct 8SEC | Eric SwayzeEvp Research | Sell Plan | 6,84930,453 held (−18%) | $69.02 | $473K | -34.4% | — |
| Oct 8SEC | Patrick R. O'neilGeneral Counsel | Sell Plan | 3,24153,889 held (−6%) | $69.27 | $225K | -34.6% | — |
| Oct 8SEC | Joseph BaroldiEvp, Chief Business Officer | Sell Plan | 1,62530,301 held (−5%) | $69.37 | $113K | -34.7% | — |
| Oct 8SEC | Brett P MoniaCEO | Sell Plan | 437179,572 held (−0%) | $69.26 | $30K | -34.6% | — |
| Oct 2SEC | Patrick R. O'neilGeneral Counsel | Sell Plan | 34,46157,130 held (−38%) | $67.69 | $2.3M | -33.1% | — |
| Oct 2SEC | Patrick R. O'neilGeneral Counsel | Sell Plan | 30,20357,130 held (−35%) | $67.69 | $2.0M | -33.1% | — |
| Oct 2SEC | Joseph H WenderDirector | Sell Plan | 16,80092,035 held (−15%) | $65.50 | $1.1M | -30.9% | — |
| Oct 2SEC | Joseph BaroldiEvp, Chief Business Officer | Sell Plan | 15,00031,926 held (−32%) | $68.01 | $1.0M | -33.4% | — |
| Oct 2SEC | Eric SwayzeEvp Research | Sell Plan | 14,14237,302 held (−27%) | $66.09 | $935K | -31.5% | — |
| Oct 2SEC | Eric SwayzeEvp Research | Sell Plan | 12,97237,302 held (−26%) | $66.23 | $859K | -31.6% | — |
| Oct 1SEC | Richard S GearyEvp, Chief Development Officer | Sell Plan | 57,90079,657 held (−42%) | $65.24 | $3.8M | -30.6% | — |
| Oct 1SEC | Elizabeth L HougenCFO | Sell Plan | 49,800110,500 held (−31%) | $65.26 | $3.2M | -30.6% | — |
| Oct 1SEC | Patrick R. O'neilGeneral Counsel | Sell Plan | 14,82757,130 held (−21%) | $64.68 | $959K | -30.0% | — |
| Oct 1SEC | Patrick R. O'neilGeneral Counsel | Sell Plan | 10,47357,130 held (−15%) | $64.54 | $676K | -29.8% | — |
Insiders at IONIS PHARMACEUTICALS INC
| Insider | Bought | Sold | Last filing | Score |
|---|---|---|---|---|
| Brett P MoniaCEO | — | $30.4M | Jun 26, 2026 | — |
| Elizabeth L HougenCFO | — | $21.1M | Mar 18, 2026 | — |
| C Frank BennettEvp, Chief Scientific Officer | — | $16.7M | Jul 9, 2026 | — |
| Richard S GearyEvp, Chief Development Officer | — | $13.4M | Nov 7, 2025 | — |
| Patrick R. O'neilGeneral Counsel | — | $9.2M | Jun 30, 2026 | — |
| Shannon L. DeversEvp, Chief Human Resources Ofc | — | $8.7M | Apr 2, 2026 | — |
| Eric SwayzeEvp Research | — | $7.5M | Jun 26, 2026 | — |
| Joseph LoscalzoDirector | — | $7.1M | May 6, 2026 | — |
| Joseph Klein IIIDirector | — | $6.0M | Jul 6, 2026 | — |
| Joseph H WenderDirector | — | $5.4M | Dec 3, 2025 | — |
| Allene M. DiazDirector | — | $5.2M | Jul 9, 2026 | — |
| Holly B. KordasiewiczEvp, Chief Development Officer | — | $4.8M | Jul 9, 2026 | — |
| Eugene SchneiderEvp, Chf Clinical Develop Ofcr | — | $3.7M | Jun 30, 2026 | — |
| Joseph BaroldiEvp, Chief Business Officer | — | $3.7M | Jun 30, 2026 | — |
| Brian BirchlerEvp, Corp And Development Ops | — | $3.6M | Apr 17, 2026 | — |
| Kyle JenneEvp, Chf Gl Pdt Str Ofcr | — | $3.3M | Apr 17, 2026 | — |
| Michael R HaydenDirector | $1.1M | — | Jul 31, 2026 | — |
| Joan E HermanDirector | — | $3.2M | Nov 20, 2025 | — |
| Spencer R BerthelsenDirector | — | $1.2M | Jun 16, 2026 | — |
| B Lynne ParshallDirector | — | $1.2M | Apr 17, 2026 | — |
IONS stock: common questions
Are IONIS PHARMACEUTICALS INC insiders buying IONS stock?
In the past 12 months, 1 insiders reported open-market purchases of IONS worth $1.1M. The latest was Director Michael R Hayden bought $801K of IONS at $53.38 — first open-market purchase in our records; raises the stake by 375%.
Are IONIS PHARMACEUTICALS INC insiders selling IONS stock?
19 insiders reported sales worth $137M over the same period.
Where does this data come from?
Every transaction comes from Form 4 filings that insiders must submit to the SEC within two business days of a trade. We pull them from SEC EDGAR every night.
What is IONS's 52-week range?
Over the past year IONS has traded between $43.30 and $86.50. It last closed at $45.28 on Oct 9, 2026.